Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells
Management of Autoimmune Conditions With Mesenchymal Stem Cells (MSCs) and CAR-T Cells
Shenzhen Geno-Immune Medical Institute
30 participants
May 15, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess the feasibility, safety and efficacy of mesenchymal stem cells (MSCs) in combination with CAR-T cells in treating autoimmune disease. Another goal of the study is to learn more about the safety and function of the MSCs combined with CAR-T cells and their long term effects in autoimmune disease patients.
Eligibility
Inclusion Criteria5
- older than 18 years of age.
- established autoimmune conditions.
- the KPS score over 80 points, and survival time is more than 3 months.
- greater than Hgb 80 g/L.
- no contraindications to blood cell collection.
Exclusion Criteria7
- accompanied with other active diseases and difficult to assess treatment response.
- bacterial, fungal, or viral infection, unable to control.
- living with HIV.
- active HBV or HCV infection.
- pregnant and nursing mothers.
- under systemic steroid treatment within a week of the treatment.
- prior failed CAR-T treatment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Infusion of 4SCAR T cells at 10\^6 cells/kg body weight and MSCs at 3x10\^6 cells via IV
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06435897